Related Experiment Videos
MIC2 analysis of small cell carcinoma
J A Lumadue1, F B Askin, E J Perlman
1Johns Hopkins Hospital, Department of Pathology, Baltimore, MD 21287.
American Journal of Clinical Pathology
|November 1, 1994
Summary
MIC2 gene product analysis can help differentiate small cell carcinomas (SCCs) from peripheral neuroectodermal tumors (PNETs). This immunohistochemical marker shows differential expression, aiding in diagnosing these overlapping neoplasms.
Area of Science:
- Oncology
- Pathology
- Molecular Biology
Background:
- Small cell carcinomas (SCCs) and peripheral neuroectodermal tumors (PNETs) present diagnostic challenges due to overlapping features.
- Accurate differentiation is crucial as SCCs and PNETs require distinct therapeutic approaches and have different prognoses.
Observation:
- This study investigated the expression of the MIC2 gene product, a cell surface antigen, in 33 small cell carcinomas.
- MIC2 is known to be reliably expressed in PNETs and Ewing's sarcoma (ES).
Findings:
- Two out of 33 SCCs exhibited positive MIC2 staining, although with lower intensity compared to PNETs and ES.
- The remaining 31 SCCs did not show MIC2 expression.
Implications:
- MIC2 expression analysis, alongside other immunohistochemical markers, may improve the diagnostic accuracy in distinguishing SCCs from PNETs.
- This approach can aid in classifying both pulmonary and extrapulmonary small cell carcinomas versus soft tissue PNETs.